New Vaccine to Protect People in the EU and Worldwide against Dengue

New Vaccine To Protect People In The Eu And Worldwide Against Dengue
On 13 October 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) expressed a positive opinion for the Dengue Tetravalent Vaccine (Live, Attenuated). This vaccine is used for the prevention of dengue disease, including lowering the risk of hospitalisation, in individuals from 4 years of age.
In the meantime, regulatory reviews about this Dengue Tetravalent Vaccine are also in progress in Latin America and Asia.
Contact RegASK for more details Read more

Have a
regulatory affairs

Regulatory Affair Icon